- : Liftango
- : 25/11/2020
Savvy Aucklanders will be able to score $1 rides on New Zealand’s newest on-demand service, MyMobigo, ahead of the service officially launching on 30 November.
MyMobigo offers commuters in East Auckland a regular on-demand service to and from the Half Moon Bay Ferry Terminal, ensuring a smooth connection to ferry services.
Greg Pollock, Transdev’s Managing Director for New Zealand, said the new app-based service would provide a quick, convenient and friendly option for people to connect to ferry services 7 days per week.
“We are excited to be bringing this new on-demand service to Auckland,” Mr Pollock said.
“MyMobigo combines state-of-the-art technology with a friendly and professional service, taking the hassle out of needing to find a park at the Ferry Terminal. Best of all, it is for less than the price of your morning coffee.
“The service is incredibly easy to use and puts the customer in control, with bookings, payments and real-time vehicle tracking available through the MyMobigo app.”
One dollar fares will be offered to customers signed up to the service to use in the first week of operation, with regular fares starting at $4.50 for adults and $3.50 for concession card holders and children. The service is being delivered by Howick and Eastern, a subsidiary of Transdev, in partnership with on-demand shared transport provider Liftango.
Sheryll Otway, General Manager for Howick and Eastern, said MyMobigo’s fleet of luxury vans provided a connection for customers to and from the Half Moon Bay Ferry Terminal.
“Our drivers have a comprehensive knowledge of the local area and will do whatever they can to provide customers with a seamless experience,” Ms Otway said.
“Customers can expect a comfy and hassle-free ride, with MyMobigo’s fleet comprising of new, modern and luxurious vehicles, equipped with USB charging and complimentary WIFI.”
Kevin Orr, CEO of Liftango, the company powering the next generation transport platform, said he was excited to be partnering with Transdev to bring new on-demand services to Auckland.
“Demand responsive transport is helping to reshape how public transport services are delivered, providing customers with the control over their journey right in the palm of their hand,” Mr Orr said.
Bookings can be 24/7 using the MyMobigo smartphone app. For more information visit www.mymobigo.co.nz.
At Transdev, we believe public transport plays an important part in how a city comes to life. Our day to day work influences our families, friends and future generations where they live, work and play. In Australasia, which covers Australia and New Zealand, we have 6,170 people who are passionate about operating our 2,010 vehicles and vessels which deliver more than 160 million customer journeys each year.
Greg Pollock is the Managing Director of New Zealand for Transdev Australasia.
About Howick & Eastern:
Howick & Eastern Buses is an urban bus operator in Auckland, with a fleet of 145 buses and runs 23 routes under contract to Auckland Transport. Throughout its long history the company has remained a leader in customer-centric innovation, introducing New Zealand’s first motorized bus in 1906.
Howick & Eastern joined the Transdev family in August 2019.
At Liftango, we believe access to transportation is a fundamental right for people in modern society. By creating better access to personalised transport through a single technology platform we enable organisations to manage and optimise vehicle movements in a more sustainable way. The result is a climate-positive, convenient & affordable demand-responsive transport system that provides better coverage and caters for all members of society. For more information visit liftango.com.
- : Dom Costello
- : Corporate Affairs Manager
- : firstname.lastname@example.org
- : 61428957214
- : Precision Driven Health
- : 18/11/2019
Precision Driven Health (PDH), New Zealand’s leading health data research initiative, has today announced it is working with MoleMap on its use of Artificial Intelligence (AI) to improve the early detection of skin cancer.
PDH Chief Executive Dr Kevin Ross says the $2 million research project will enhance the AI algorithm that MoleMap has developed to differentiate cancerous skin lesions from benign lesions.
“Every year nearly 400 New Zealanders die from skin cancer and studies indicate that early detection could have greatly improved the chance of survival in the majority of cases,” Dr Ross says.
“This project has the potential to increase access to skin checks by extending the technology for use at the primary care and general practitioner level, and thereby enabling more New Zealanders access to early detection for skin cancer.”
MoleMap Chief Technology Officer Adrian Bowling says the PDH partnership builds on initial research developed with IBM Research in Melbourne on a small subset of data.
“The partnership with PDH will provide us with access to a larger, wider set of data as we continue to work with experts at the University of Otago in Dunedin, and Monash University in Melbourne, to enhance this ground-breaking technology,” Mr Bowling says.
Computer-based systems for recognising malignant moles have been developed over the past 20 years but have had limited uptake. With the advent of AI, combined with large databases and “deep learning” algorithms, new opportunities for the use of these technologies can be explored.
“Published studies and our own research suggest that it is possible for a system-based AI to be at least as good as dermatologists in differentiating cancerous lesions from benign lesions,” Mr Bowling says.
The research project will include clinical trials in New Zealand and Australia once the algorithm has been enhanced. As essential part of the research is to ensure that the unique population of Aotearoa is taken into account and all skin types will be tested.
Dr Ross says that, as with all PDH projects, a key focus is applying new techniques in data science to advance Māori health outcomes.
“Māori do not have a high incidence of melanoma; however, there is a high mortality rate for those who have melanoma. This has generally been seen as a result of Māori, like many other New Zealanders, presenting with later stage melanoma when it is difficult to cure. Being able to better detect melanoma in Māori could help decrease this mortality risk and save lives.”
For more information and/or an interview with Dr Kevin Ross, contact:
About Precision Driven Health
The Precision Driven Health partnership (PDH), established in March 2016, is one of the most ambitious data science research initiatives to be undertaken in New Zealand. The partnership unites the health IT sector with health providers and universities to create health and commercial opportunities for New Zealanders. Research is focused on applying new data science techniques to understand the massive volume of data about an individual captured by health information systems, consumer devices, social networks, genetic testing, and other sources. Visit our website precisiondrivenhealth.com.
MoleMap’s team of leading dermatologists and melanographers have been detecting and diagnosing melanoma for over two decades, using a unique skin mapping system that’s designed to track changes in the skin over time. MoleMap has over 40 clinics around New Zealand serving over 250,000 patients nationwide. Visit our website www.molemap.co.nz.
- : Nicole Gray
- : Communications Specialist
- : email@example.com
- : 0276177235
- https://twitter.com/HealthPrecision | https://www.linkedin.com/company/precision-driven-health/